Tags : NueLara

NeuClone Reports Dosing of NeuLara (proposed biosimilar, ustekinumab) in P-I

Shots: Australian Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) scheme is responsible for conducting the NeuLara P-I trial and is being conducted across 200 healthy volunteers assessing PK and safety of US- and EU-sourced Stelara NeuClone’s NeuLara is the second biosimilar in pipeline to enter in clinical development and is developed in partnership with […]Read More